Our dream at Sanguis is to revolutionize the care of cancer patients with a simple but powerful technology. We are thankful to our various collaborators and funding sources, who have helped us put together a strong initial product.
Our team won the Weiss Tech House Innovation Fund in Fall 2016
We were the 2016 Winners of the Wharton Innovation Fund, and were accepted to the Wharton Venture Initiation Program-Community
Accepted to the Spring 2017 Cohort of Philadelphia University City Science CEnter's P1V program
Participants in the Fall 2016 PennApps Accelerator
We were honored to be accepted to the Port Incubator Program and subsequently described by the Philadelphia Business Journal as breakthrough startup working to improve cancer treatment.
Technical.ly Media Listed Sanguis as 1 of 4 Philadelphia startups to watch out for in 2017.
Sanguis was selected as an I-corps winner during the program's Fall 2016 cycle. We are thankful to Penn I-corps for their support of our customer discovery activities.
Winners of the 2017 "Big Ideas Through Small Technology" Grant and recognized as the Philadelphia area’s brightest minds to prototype innovative technology through the usage of nanotechnology.
Sanguis became a member of PACT in Summer 2017, and aims to drive innovation and entrepreneurship in the region.
Sanguis was chosen as a Penn Health-X Venture Fund Recipient in 2017.
Sanguis was selected as the Top 10 Finalists out of >140 companies, and won the First Prize in the Elevator Pitch Competition at Baylor New Venture Competition in Waco, Texas
Sanguis Won the 2018 PennVention Startup Competition organized by the University of Pennsylvania School of Engineering and Applied Sciences and the Weiss Tech House.
Sanguis won the Perelman Grand Prize and emerged winners at the Penn Wharton Startup Showcase in April 2018!